Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« The Merck Index | Main | Mipomersen In Trouble »

December 14, 2012

LaMattina on Angell

Email This Entry

Posted by Derek

John LaMattina takes on Marcia Angell and her recent interview. It sounds like he made it farther into the podcast than I could:

“The drug companies do almost no innovation nowadays….. All they have to do is the late development. And that’s the clinical trials. Now that is an expensive part of the process. But it is not an innovative part of the process.”

. . .innovation doesn’t only occur in discovery research labs. Translating laboratory science into meaningful clinical science is quite challenging. Yet, many of the new drugs that are now being approved to treat various cancers have been developed through innovative paradigms and experimental methods developed by scientists and physicians in the pharmaceutical industry. For Angell to dismiss this so blithely is insulting.

"Insulting" is the word, and I have little doubt that this is a deliberate feature of Angell's take on the drug industry. Language like this gets attention. It brings in page views; it sells books. It gets you speaking engagements. As far as I can see, you bring in Marcia Angell to watch her attack pharmaceutical companies - that's her niche.

Comments (5) + TrackBacks (0) | Category: Why Everyone Loves Us


COMMENTS

1. Keith Robison on December 14, 2012 9:32 AM writes...

Derek, you obviously need to correct your recent item on the Syk inhibitor trial. You wrote that this was a head-to-head trial against Humira, but Dr. Angell is quite adamant that pharma always runs their trials comparing to a placebo, so you must have made a mistake!

Permalink to Comment

2. johnnyboy on December 14, 2012 9:59 AM writes...

Exactly. The first instinct of knowledgeable industry people upon hearing Angell's diatribes is to patiently refute her statements point by point with facts - but this approach is completely futile, as she has built herself and her career up as an attack dog and a pamphleteer, and people like that are entirely immune to facts. Se couldn't possibly accept any fact contradicting her discourse, as it would directly threaten her livelihood.

Permalink to Comment

3. Perdurabo on December 14, 2012 12:25 PM writes...

There's no doubt that there's a lot that the pharmaceutical field needs to do better. I'm a big critic, but I continue to work to support it because that's the only way the real improvements will be realized. To simply denounce the whole field in it's entirety using baseless claims of conspiratorial greed is of absolutely no use to anyone (except perhaps for Angell's speaking career): it does not illustrate the scientific and sociological issues that need to be addressed, nor does it serve to educate those who are unfamiliar with the field and who may look to gather information from people with "Dr" of "PhD" attached to their name. This is ironic, given that she holds a teaching title at an educational facility. It's like she's a latter-day Neo-Macarthiest with a pharmaceutical flavor. The fact that her arguments are so full of inaccuracies is also telling: if you have to misrepresent the truth to get your point across, then your point is invalid.

Permalink to Comment

4. drug_hunter on December 14, 2012 6:06 PM writes...

The important question is whether she has any influence with policy-makers. If not, she is just an extreme form of gadfly -- very annoying, shrill, lying, doing some damage, etc. but not the end of the world.

Permalink to Comment

5. CMCguy on December 14, 2012 7:17 PM writes...

#4 d_h I have no concrete information on this however would observationally suggest Angell and her pharmacritic cohorts have already had influence on many people/groups. Would include legislative and government officials (based on new or proposed laws, hearings, promoting academic drug discovery), AMA, Harvard Med school, media (who constantly echo her statements/conclusions without any counter-balance/truthfulness) and public opinion (who buy the big bad pharma mantra).

The Pharma industry and many individual companies have opened the doors to many fair criticisms thru misdeeds or poor decisions however much of what Angell drivels out is so off the mark it must be challenged and glad bloggers like Derek and LaMattina are effective voices against such crap.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
XKCD on Protein Folding
The 2014 Chemistry Nobel: Beating the Diffraction Limit
German Pharma, Or What's Left of It
Sunesis Fails with Vosaroxin
A New Way to Estimate a Compound's Chances?
Meinwald Honored
Molecular Biology Turns Into Chemistry
Speaking at Northeastern